APS.TO - Aptose Biosciences Inc.
| Previous Close | 2.5700 |
| Open | 2.5400 |
| Bid | 2.60 x 0 |
| Ask | 2.62 x 0 |
| Day's Range | 2.5400 - 2.6200 |
| 52 Week Range | 2.3400 - 5.9700 |
| Volume | 36,317 |
| Avg. Volume | 29,038 |
| Market Cap | 97.828M |
| Beta (3Y Monthly) | 0.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.85 |
| Earnings Date | Nov 12, 2018 - Nov 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- GlobeNewswire•3 days ago
Aptose to Present at the 8th Annual SVB Leerink Global Healthcare Conference
SAN DIEGO and TORONTO, Feb. 19, 2019 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.
- ACCESSWIRE•25 days ago
Today's Research Reports on Oncolytics Biotech, Delivra, Aptose Biosciences and ProMIS Neurosciences
NEW YORK, NY / ACCESSWIRE / January 28, 2019 / The Market Wealth Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
- Simply Wall St.•29 days ago
Does Market Volatility Impact Aptose Biosciences Inc.’s (TSE:APS) Share Price?
If you own shares in Aptose Biosciences Inc. (TSE:APS) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- GlobeNewswire•2 months ago
Aptose Biosciences to Present at Biotech Showcase™ 2019 Conference
SAN DIEGO and TORONTO, Jan. 02, 2019 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.
- ACCESSWIRE•2 months ago
Today's Research Reports on Aptose Biosciences, ProMIS Neurosciences, Emblem and BELLUS Health
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...
- GlobeNewswire•2 months ago
Aptose Presents Highlights From CG-806 KOL Event
SAN DIEGO and TORONTO, Dec. 12, 2018 -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a Key Opinion Leader (KOL) breakfast featuring a presentation.
- GlobeNewswire•3 months ago
OHSU and Aptose Present New CG-806 Preclinical Data at ASH 60th Annual Meeting
PORTLAND, Ore. and SAN DIEGO, Dec. 03, 2018 -- Oregon Health & Science University (OHSU) and Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the.
- GlobeNewswire•3 months ago
Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting
SAN DIEGO and TORONTO, Dec. 03, 2018 -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the presentation of preclinical data from research led by The.
- GlobeNewswire•3 months ago
Aptose Biosciences Doses First Patient in Re-Initiation of Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies
“We are pleased to announce the successful re-initiation of patient dosing in our clinical trial with APTO-253, our first-in-class inhibitor of the MYC oncogene that has the potential to benefit a large patient population across various therapeutic areas, and we look forward to providing updates moving forward,” commented William G. Rice, Ph.D., Chairman, President and CEO. “As the clinical protocol requires only one patient at each of the two lowest dose levels, we have and will continue to carefully select patients for those first two dose levels.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of APS.TO earnings conference call or presentation 7-Nov-18 1:00pm GMT
Q3 2018 Aptose Biosciences Inc Earnings Call
- ACCESSWIRE•5 months ago
Today's Research Reports on ESSA Pharma, Oncolytics Biotech, Aptose Biosciences and OrganiGram
NEW YORK, NY / ACCESSWIRE / October 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
- ACCESSWIRE•5 months ago
Today's Research Reports on Aralez Pharmaceuticals, OrganiGram Holdings, Oncolytics Biotech and Aptose Biosciences
NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
- ACCESSWIRE•6 months ago
Today's Research Reports on Emblem, OrganiGram Holdings, Oncolytics Biotech and Aptose Biosciences
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
- Simply Wall St.•7 months ago
Breaking Down Aptose Biosciences Inc’s (TSE:APS) Ownership Structure
In this article, I’m going to take a look at Aptose Biosciences Inc’s (TSE:APS) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
- Baystreet•7 months ago
Stocks in play: Aptose Biosciences Inc
Announced that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer, and Gregory ...
